Therapeutic Potential of Agonists and Antagonists of A1, A2a, A2b and A3 Adenosine Receptors.


Journal

Current pharmaceutical design
ISSN: 1873-4286
Titre abrégé: Curr Pharm Des
Pays: United Arab Emirates
ID NLM: 9602487

Informations de publication

Date de publication:
2019
Historique:
received: 02 06 2019
accepted: 04 07 2019
pubmed: 25 7 2019
medline: 1 5 2020
entrez: 24 7 2019
Statut: ppublish

Résumé

Adenosine is a naturally occurring nucleoside and an essential component of the energy production and utilization systems of the body. Adenosine is formed by the degradation of adenosine-triphosphate (ATP) during energy-consuming processes. Adenosine regulates numerous physiological processes through activation of four subtypes of G-protein coupled membrane receptors viz. A1, A2A, A2B and A3. Its physiological importance depends on the affinity of these receptors and the extracellular concentrations reached. ATP acts as a neurotransmitter in both peripheral and central nervous systems. In the peripheral nervous system, ATP is involved in chemical transmission in sensory and autonomic ganglia, whereas in central nervous system, ATP, released from synaptic terminals, induces fast excitatory postsynaptic currents. ATP provides the energetics for all muscle movements, heart beats, nerve signals and chemical reactions inside the body. Adenosine has been traditionally considered an inhibitor of neuronal activity and a regulator of cerebral blood flow. Since adenosine is neuroprotective against excitotoxic and metabolic dysfunctions observed in neurological and ocular diseases, the search for adenosinerelated drugs regulating adenosine transporters and receptors can be important for advancement of therapeutic strategies against these diseases. This review will summarize the therapeutic potential and recent SAR and pharmacology of adenosine and its receptor agonists and antagonists.

Identifiants

pubmed: 31333104
pii: CPD-EPUB-99660
doi: 10.2174/1381612825666190716112319
doi:

Substances chimiques

Neuroprotective Agents 0
Purinergic P1 Receptor Agonists 0
Purinergic P1 Receptor Antagonists 0
Receptors, Purinergic P1 0
Adenosine Triphosphate 8L70Q75FXE
Adenosine K72T3FS567

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2892-2905

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Sumit Jamwal (S)

School of Pharmacy and Emerging Sciences, Baddi University of Emerging Sciences and Technologies, Baddi, India.

Ashish Mittal (A)

Department of Pharmaceutical Sciences, M.R.S. Punjab Technical University, Bathinda, Punjab, India.

Puneet Kumar (P)

Department of Pharmaceutical Sciences, M.R.S. Punjab Technical University, Bathinda, Punjab, India.

Dana M Alhayani (DM)

Faculty of Pharmacy, Philadelphia University, PO Box - 1, 19392, Amman, Jordan.

Amal Al-Aboudi (A)

Faculty of Science, The University of Jordan, Amman, 11942, Jordan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH